Pfizer secures 29 million dollars from SAC Capital insider trading settlement
Pfizer to receive 29 million dollars from a settlement involving Steven A. Cohen's former hedge fund. The deal ends a dispute over a 2013 insider trading case.
Insights:
Pfizer Inc. has agreed to accept a $29 million payment to resolve a dispute with the U.S. Securities and Exchange Commission concerning leftover funds from a 2013 insider-trading settlement involving SAC Capital Management. The agreement, reached on February 10, 2026, concludes an appeal by the pharmaceutical company and finalizes the distribution of a $75.2 million balance remaining in the United States 
US.
US.Under the terms of the settlement, $29 million will be allocated to Pfizer, while the remaining $46.2 million will be directed to the U.S. Treasury. This resolution effectively ends Pfizer’s challenge to a prior allocation decision and a November 2024 ruling by Judge Victor Marrero. The funds represent restitution tied to the convicted trades of Mathew Martoma, whose activities led to the high-profile enforcement action over a decade ago.
